Oncogenesis
Scope & Guideline
Connecting the dots in cancer biology and treatment.
Introduction
Aims and Scopes
- Molecular Mechanisms of Cancer:
Research articles delve into the intricate molecular pathways that contribute to cancer initiation, progression, and metastasis, including studies on signaling pathways, genetic mutations, and epigenetic modifications. - Cancer Therapeutics and Resistance:
The journal publishes findings related to the development of novel therapeutic approaches, including targeted therapies and immunotherapies, as well as mechanisms of drug resistance that hinder treatment efficacy. - Cancer Stem Cells and Tumor Microenvironment:
A significant focus is placed on cancer stem cells, their role in tumor heterogeneity, and the influence of the tumor microenvironment on cancer progression and treatment response. - Advancements in Diagnostic and Prognostic Techniques:
The journal highlights innovative diagnostic tools and prognostic markers that facilitate early detection and personalized treatment strategies for various cancer types. - Translational Research and Clinical Applications:
Oncogenesis emphasizes studies that bridge laboratory findings with clinical applications, aiming to translate basic research into effective cancer treatments.
Trending and Emerging
- Targeting the Tumor Microenvironment:
Research is increasingly focusing on the tumor microenvironment and its role in cancer progression, therapy resistance, and immune evasion, highlighting the importance of understanding the interactions between tumor cells and their surrounding stromal cells. - Cancer Metabolism and Bioenergetics:
There is a growing trend towards investigating the metabolic reprogramming of cancer cells, with studies exploring how alterations in metabolism contribute to tumor growth and therapeutic resistance. - Immunotherapy and Immune Checkpoint Inhibition:
The exploration of immunotherapeutic strategies, particularly immune checkpoint inhibitors, is rapidly expanding, with research dedicated to understanding mechanisms of action, resistance, and combination therapies. - Precision Medicine and Personalized Therapy:
The journal is witnessing an increase in studies aimed at developing personalized treatment strategies based on genetic and molecular profiling of tumors, paving the way for more effective and tailored therapies. - Role of Non-Coding RNAs in Cancer:
Emerging research on the functional roles of non-coding RNAs (such as microRNAs and long non-coding RNAs) in cancer biology is gaining traction, providing insights into their potential as therapeutic targets and biomarkers.
Declining or Waning
- Traditional Chemotherapy Studies:
Research focused solely on traditional chemotherapy regimens is becoming less prevalent, as newer targeted therapies and immunotherapies gain prominence in cancer treatment, leading to a reduced emphasis on conventional approaches. - Single Agent Studies:
There is a noticeable decrease in publications centered around the efficacy of single-agent treatments, as the field increasingly prioritizes combination therapies that enhance treatment outcomes and reduce resistance. - Basic Histopathological Studies:
Basic histopathological studies that do not integrate molecular or genetic insights are being overshadowed by more comprehensive approaches that utilize multi-omics and systems biology to understand cancer biology. - Epidemiological Studies without Molecular Insights:
Epidemiological studies that lack a molecular component are becoming less frequent, as the emphasis shifts toward understanding the biological mechanisms driving cancer disparities and outcomes.
Similar Journals
Annual Review of Cancer Biology
Elevating Understanding in Cancer ResearchAnnual Review of Cancer Biology is a pivotal journal published by Annual Reviews, specializing in the rapidly evolving field of cancer research. With an impact factor positioned in the distinguished Q1 quartile of Cancer Research, Cell Biology, and Oncology categories, this journal ensures that it showcases the highest quality of scholarly contributions. Indexed in Scopus, it ranks among the top in its fields, reflecting its strong influence and relevance, with remarkable percentiles indicating its esteemed position within the research community. Although not an open-access journal, it provides a comprehensive platform for advancing the frontiers of cancer biology through rigorously curated reviews, highlighting key developments, breakthroughs, and future directions that inform both academia and clinical applications. As a valuable resource for researchers, professionals, and students, the Annual Review of Cancer Biology serves as an essential guide for understanding and addressing the complexities of cancer biology today.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
Elevating the standards of cancer research and treatment.The JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, published by BMC, is a leading open-access journal dedicated to advancing the field of cancer research and oncology. Since its inception in 1982, this esteemed journal has fostered innovation and collaboration in the scientific community, as evidenced by its outstanding impact factor and position in the Q1 quartile for both Cancer Research and Oncology categories in 2023. With a proud commitment to disseminating high-quality research, the journal operates under an open-access model, ensuring that findings are readily accessible to researchers, healthcare professionals, and students worldwide. The journal has established a distinguished reputation, ranking 23rd out of 404 in Medicine oncology and 16th out of 230 in Biochemistry, Genetics, and Molecular Biology (cancer research), showcasing its importance and influence in guiding the future of cancer treatment and research. With the aim of bridging experimental and clinical research, this journal invites submissions that push the boundaries of our understanding of cancer biology and therapy.
CURRENT CANCER DRUG TARGETS
Unveiling novel therapeutic avenues in the fight against cancer.CURRENT CANCER DRUG TARGETS is a prominent academic journal published by Bentham Science Publishers Ltd, focusing on the critical intersection of cancer research and innovative drug development. Since its inception in 2001, this journal has offered a platform for the dissemination of cutting-edge research aimed at advancing targeted cancer therapies, contributing significantly to the fields of Cancer Research, Drug Discovery, Oncology, and Pharmacology. With a respectable impact factor and consistent ranking in its respective categories, including Q2 in Drug Discovery and Pharmacology, it positions itself as an invaluable resource for researchers, clinicians, and students alike. CURRENT CANCER DRUG TARGETS is dedicated to enhancing our understanding of novel therapeutic targets and methods, thereby fostering a collaborative environment for knowledge exchange in the ever-evolving landscape of cancer treatment.
Advances in Cancer Biology-Metastasis
Unraveling the Secrets of Metastasis.Advances in Cancer Biology-Metastasis is an emerging journal published by Elsevier, aimed at advancing our understanding of the complexities of cancer biology, with a specific focus on the mechanisms and pathways related to metastasis. With an E-ISSN of 2667-3940, this journal offers a platform for researchers, professionals, and students in the fields of Cancer Research and Cell Biology to disseminate innovative findings and discuss novel therapeutic approaches. Though currently classified in the Q4 quartile across both Cancer Research and Cell Biology categories, the journal aspires to enhance its impact through rigorous peer review and high-quality publication. Positioned to cover the years from 2021 to 2024, it seeks to bridge gaps in foundational knowledge and promote collaborative research efforts that could pivot the current understanding of cancer metastasis. Researchers are encouraged to take advantage of this platform to advocate for advancements in cancer biology, making significant contributions that can influence both academic and clinical practices.
ONCOGENE
Advancing Cancer Research Through Innovative InsightsONCOGENE is a premier peer-reviewed journal published by SpringerNature, serving as a crucial platform for innovative research within the fields of Cancer Research, Genetics, and Molecular Biology. With an impressive Impact Factor and a distinguished Q1 ranking across major categories, ONCOGENE publishes cutting-edge studies aimed at unraveling the complexities of cancer biology and genetic mechanisms. The journal has been a vital resource for the academic community since its inception in 1987, and it continues to foster rigorous scientific discussions and collaborations. Researchers, professionals, and students can access a wealth of critical insights and advances in cancer genomics and therapeutic approaches, cementing ONCOGENE’s role as a leading voice in the landscape of biomedical research. For comprehensive academic research, ONCOGENE remains an indispensable source of knowledge with contributions that significantly impact the evolution of cancer research and treatment strategies.
CELLULAR & MOLECULAR BIOLOGY LETTERS
Fostering Collaboration in the World of Molecular DiscoveriesCELLULAR & MOLECULAR BIOLOGY LETTERS, published by BMC, is a premier open-access journal dedicated to disseminating high-quality research in the fields of Biochemistry, Cell Biology, and Molecular Biology. Established in 1996, the journal has emerged as a leader in its domain, boasting an impressive Q1 ranking across three critical categories as of 2023, reflecting its significant impact within the scientific community. With an ISSN of 1425-8153 and an E-ISSN of 1689-1392, it offers accessible research findings to a global audience, having been open access since 2013. Situated in the United Kingdom, at CAMPUS, 4 CRINAN ST, LONDON N1 9XW, the journal continues to serve as a vital resource for researchers, professionals, and students, contributing to advancements in the understanding of cellular and molecular processes. By providing a platform for original research, reviews, and short communications, CELLULAR & MOLECULAR BIOLOGY LETTERS plays a crucial role in fostering dialogue and collaboration within the scientific community.
CANCER SCIENCE
Leading the charge in innovative cancer treatment solutions.Cancer Science, an esteemed journal published by Wiley, stands at the forefront of oncology research, boasting an impressive impact factor and a classification in the Q1 category for its contributions in Cancer Research, Medicine, and Oncology as of 2023. Since its inception in 2003 and transitioning to an Open Access model in 2014, the journal has facilitated global dissemination of critical research findings, ensuring that vital information remains accessible to researchers, clinicians, and students alike. With its comprehensive scope covering cutting-edge discoveries in cancer biochemistry, genetics, and molecular biology, Cancer Science is recognized for its rigorous peer-review process and significant contributions to advancing our understanding of cancer. The journal, located at 111 River St, Hoboken, NJ, is an essential resource for anyone dedicated to improving treatment outcomes and pushing the boundaries of cancer research.
Cancer Genetics
Unraveling the Genetic Mysteries of CancerCancer Genetics is an esteemed peer-reviewed journal dedicated to advancing the field of cancer research through the lens of genetics. Published by Elsevier Science Inc and available in both print (ISSN: 2210-7762) and online (E-ISSN: 2210-7770), this journal aims to provide a platform for the dissemination of high-quality studies that unravel the genetic underpinnings of cancer. Since its inception in 2011, Cancer Genetics has become a significant resource for researchers, professionals, and students with a shared interest in understanding the intricate relationship between genetics and oncogenesis. With an impact factor that reflects its influence, the journal has maintained a Q3 ranking in Cancer Research, Genetics, and Molecular Biology as of 2023, indicating its growing importance in these fields. Additionally, the journal offers open access options to ensure that crucial findings are easily accessible to the global research community. By bridging the gap between genetics and cancer studies, Cancer Genetics plays a pivotal role in fostering innovation and collaboration among scientists and clinicians striving to improve cancer diagnosis and treatment.
MOLECULAR CANCER THERAPEUTICS
Advancing cancer therapy through molecular insights.MOLECULAR CANCER THERAPEUTICS, published by the American Association for Cancer Research, is a premier journal dedicated to advancing the field of cancer research and therapy since 2001. With a notable impact factor reflecting its high-quality content, this journal stands out in the Q1 category for both Cancer Research and Oncology as of 2023. Researchers, clinicians, and students interested in innovative treatment strategies and molecular mechanisms can find valuable insights within its pages, bolstered by a rigorous peer-review process and a global perspective on cancer therapeutic developments. Although the journal operates under a subscription model, it provides comprehensive access to cutting-edge studies and reviews that drive forward the understanding of cancer biology and treatment modalities. The journal's impressive Scopus rankings further validate its influence within both oncology and the broader cancer research community, making it an indispensable resource for anyone committed to combating cancer through science.
INTERNATIONAL JOURNAL OF CANCER
Catalyzing progress in the fight against cancer.INTERNATIONAL JOURNAL OF CANCER, published by Wiley, stands as a premier platform for the dissemination of cutting-edge research in the fields of cancer research and oncology. With an impressive impact factor reflecting its rigorous peer-review process and significant contribution to the scientific community, this journal is categorized in Q1 for both Cancer Research and Oncology as of 2023. It boasts notable rankings, being placed 38th among 404 journals in Medicine - Oncology and 32nd among 230 in Biochemistry, Genetics, and Molecular Biology - Cancer Research, positioning it within the 90th and 86th percentiles, respectively. Since its inception in 1966 and continuing to 2024, the journal has played a pivotal role in advancing our understanding of cancer biology, treatment modalities, and innovative therapeutic approaches. While it operates under a subscription model, the journal is committed to making valuable research accessible to a broader scientific audience. Researchers, professionals, and students alike will find the INTERNATIONAL JOURNAL OF CANCER an essential resource for staying abreast of the latest advancements in cancer science.